"Making Real-World Treatment Decisions About Schizophrenia: The CATIE Trial" psychCME TV Premieres Wednesday, November 9, 2005
psychCME and CME Outfitters are pleased to announce an upcoming live and interactive CE activity titled "Making Real-World Treatment Decisions About Schizophrenia: The CATIE Trial." Offered as a live satellite broadcast, webcast, and telephone audioconference premiering Wednesday, November 9, 2005, from 12:00 p.m.–1:00 p.m. ET, the activity will focus on providing current and clinically relevant data about the efficacy and cost-effectiveness of a variety of different antipsychotics used to treat schizophrenia.
Rockville, MD (PRWEB) November 1, 2005 -- psychCME and CME Outfitters are pleased to announce an upcoming live and interactive CE activity titled "Making Real-World Treatment Decisions About Schizophrenia: The CATIE Trial."
Offered as a live satellite broadcast, webcast, and telephone audioconference premiering Wednesday, November 9, 2005, from 12:00 p.m.–1:00 p.m. ET, the activity will focus on providing current and clinically relevant data about the efficacy and cost-effectiveness of a variety of different antipsychotics used to treat schizophrenia. The recorded satellite broadcast will re-air from 3:00 p.m.–4:00 p.m. ET. This CE activity will be available as an archived webcast, podcast, and telephone audioconference shortly after the live broadcast, and available as a videotape and multimedia CD-ROM in December.
Participation in this activity is free, as is obtaining a CE certificate; however, registration is required. Three forms of registration are accepted:
Fax: View the activity details page at http://www.psychCME.net/cmea.asp?ID=120, print and complete the activity details form, and fax to 240.243.1033
Online: Visit the psychCME TV page at http://www.psychCME.net
Phone: Call 877.CME.PROS (877.263.7767)
Statement of Need:
Schizophrenia is a severe, debilitating mental illness, complicated by the challenge of achieving treatment efficacy and compliance. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial was designed so that researchers could gain important information about long-term outcomes and cost-effectiveness of a number of medications already used to treat schizophrenia. CATIE was launched in 2000, and is a double-blind, randomized comparison of atypical antipsychotics with each other and with a conventional antipsychotic, perphenazine. It is considered a "practical" clinical trial because participants were recruited from the community at large and because the interventions tested are already in widespread use. Patients were followed for 18 months in each phase (Phase 1-3); if at any time during the trial an assigned medication was ineffective or not well tolerated, patients were re-randomized to other treatment pathways. Data collection in the study was completed in December 2004 and data analyses are being carried out through 2005.
In this landmark psychCME TV activity, CATIE researchers will review the Phase I data and explain how these data can be interpreted so clinicians can make evidence-based decisions about treating patients with schizophrenia.
Faculty:
Jeffrey A. Lieberman, MD
Chairman, Department of Psychiatry
College of Physicians and Surgeons, Columbia University
Director, New York State Psychiatric Institute
Director, Lieber Center for Schizophrenia Research
Psychiatrist-in-Chief at New York Presbyterian Hospital & Columbia University Medical Center
New York, NY
Zafar Sharif, MD
Assistant Professor of Clinical Psychiatry
Director of the Clinical Trial Program
Department of Psychiatry
College of Physicians and Surgeons, Columbia University
New York, NY
psychCME Moderator:
Prakash S. Masand, MD
Consulting Professor of Psychiatry
Duke University Medical Center
Durham, NC
Learning Objectives:
At the end of this CE activity, participants should be able to:
- Assess the evidence for the efficacy of the different treatment options in the CATIE trial.
- Utilize evidence-based judgement to assess the tolerability profile of different treatments in the CATIE trial.
- Recognize the clinical merit of trials that include participants who reflect a wide range of disease states and phenomenology.
Target Audience:
Physicians, physician assistants, nurse practitioners, nurses, psychologists, social workers, certified case managers, pharmacists, and other healthcare professionals with an interest in mental health.
Commercial Support:
CME Outfitters, LLC, gratefully acknowledges an educational grant from Pfizer Inc. in support of this CE activity.
Credit Information:
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CME Outfitters, LLC, designates this educational activity for a maximum of 1.0 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
Note to Physician Assistants: AAPA accepts Category I credit from AOACCME, Prescribed credit from AAFP, and AMA Category I CME credit for the PRA from organizations accredited by ACCME.
CNE Credit (Nurses):
This Educational Activity is presented by CME Outfitters, LLC, which has been approved as a provider of continuing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. It has been assigned code 5UYSJZ-PRV-0460. 1.2 contact hours (Pharmacology)
CEP Credit (Psychologists):
CME Outfitters, LLC, is approved by the American Psychological Association to offer continuing education for psychologists. CME Outfitters, LLC, maintains responsibility for the program. 1.0 CE credits
NASW Credit (Social Workers):
This program was approved by the National Association of Social Workers (provider #886407722) for 1 continuing education contact hour.
CCMC Credit (Certified Case Managers):
This program has been approved for 1 hour by the Commission for Case Manager Certification (CCMC).
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hours (0.1 CEUs)
Universal Program Number: 376-999-05-015-L01 (live presentation) 376-999-05-015-H01 (recorded programs)
To receive credit, participants must review all activity materials in their entirety, score 70% or above on a post-test, and fully complete and return both the credit request form and activity evaluation. A certificate or statement of credit will be mailed within 4-6 weeks to all who successfully complete these requirements.
About CME Outfitters:
CME Outfitters is a full service healthcare communications agency providing continuing education content development, production, marketing, accreditation, and project management services to the healthcare industry. Among its many collaborative ventures, CME Outfitters enjoys an exclusive role in producing, certifying, and supporting the popular psychCME series of educational activities originally developed at Duke University Medical Center. For more information on CME Outfitters, including a complete calendar of its free award-winning educational activities, please visit http://www.cmeoutfitters.com, or call 877.CME.PROS (877.263.7767).
To view all of CME Outfitters' recent press releases, visit http://www.cmeoutfitters.com and click on "CME Outfitters in the News" or visit http://www.prweb.com and search for "CME Outfitters."
psychCME EXTRA, a weekly e-newsletter published by CME Outfitters, is a convenient way to stay informed of all psychCME news and information. To subscribe, visit http://www.cmeoutfitters.com and click on "Register for Updates."
Contact: Jessica Primanzon
CME Outfitters, LLC
240.243.1308 direct
240.243.1033 fax
###
|
